# A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

> **NCT01799278** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 60 (actual)

## Conditions studied

- Small Cell Prostate Cancer
- Neuroendocrine Prostate Cancer
- Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

## Interventions

- **DRUG:** MLN8237

## Key facts

- **NCT ID:** NCT01799278
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2016-07
- **Final completion:** 2017-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01799278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01799278, "A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01799278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*